Immunocore Holdings plc

Name: Immunocore Holdings plc standardized financial statements, quarterly
Creator: Listed

IMCRNasdaqCIK 1671927HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$115.9m, Q2 FY2026

Operating income−$3.0m, Q2 FY2026

Net income−$808.0k, Q2 FY2026

Immunocore Holdings plc, income statement, quarterly
Line item	Unit	period not labelled2023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	64.9	70.2	70.5	75.4	80.2	84.1	93.9	98.0	104	104	107	116
Cost of revenue	$m	0.3	0.2	0.2	1.7	0.4	0.3	0.8	1.0	0.5	2.7	0.4	1.1
Research and development	$m	43.2	45.6	57.5	51.1	52.8	60.9	56.5	69.0	70.6	78.8	61.1	73.9
Selling, general and administrative	$m	35.5	41.4	39.3	38.6	35.5	42.3	40.2	42.8	39.8	42.6	37.9	43.9
Operating income	$m	(14.1)	(17.1)	(26.5)	(16.0)	(8.5)	(19.5)	(3.6)	(14.9)	(7.2)	(19.7)	7.3	(3.0)
Interest expense	$m	1.3	1.3	3.2	4.3	4.3	7.0	3.0	3.0	3.0	3.1	3.1	3.1
Income tax	$m	(0.2)	(5.9)	0.4	1.5	(2.6)	(1.1)	1.1	0.6	0.5	14.3	0.3	0.3
Net income	$m	0.9	(19.7)	(24.4)	(11.6)	8.7	(23.8)	5.0	(10.3)	(0.2)	(30.1)	13.0	(0.8)
Diluted EPS	$ per share	0.02	not reported	(0.49)	(0.23)	0.17	not reported	0.10	(0.20)	0.00	not reported	0.25	(0.02)
Basic EPS	$ per share	0.02	not reported	(0.49)	(0.23)	0.17	not reported	0.10	(0.20)	0.00	not reported	0.26	(0.02)

Balance sheet

Cash and equivalents$484.9m, Q2 FY2026

Long-term debt$438.7m, Q3 FY2024

Shareholders' equity$419.8m, Q2 FY2026

Immunocore Holdings plc, balance sheet, quarterly
Line item	Unit	FY20232023-12-31	period not labelled2024-02-02	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	443	not reported	833	505	538	456	477	488	498	468	453	485
Current assets	$m	529	not reported	926	957	1,006	930	949	1,002	1,023	997	1,004	1,051
Total assets	$m	597	not reported	994	1,023	1,085	1,010	1,028	1,082	1,103	1,067	1,072	1,119
Current liabilities	$m	139	not reported	155	185	266	212	149	170	170	247	240	235
Total liabilities	$m	228	not reported	634	664	707	649	650	694	706	686	678	700
Long-term debt	$m	not reported	403	453	453	439	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	369	not reported	360	359	378	361	378	388	397	381	394	420

Cash flow

Operating cash flow$15.9m, Q2 FY2026

Capital expenditure$786.0k, Q2 FY2026

Immunocore Holdings plc, cash flow, quarterly
Line item	Unit	period not labelled2023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	10.1	(17.7)	(4.6)	23.5	21.1	(14.0)	0.4	26.0	(4.5)	(32.7)	(13.8)	15.9
Capital expenditure	$m	0.2	0.8	0.4	0.3	0.8	3.6	0.3	0.4	0.7	2.9	1.8	0.8

Diluted shares (weighted)50.97m, Q2 FY2026

Immunocore Holdings plc, shares, quarterly
Line item	Unit	period not labelled2023-03-31	period not labelled2023-06-30	period not labelled2023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	48.2	48.7	54.2	49.9	50.0	52.8	51.9	50.3	50.4	52.9	51.0

Shares outstanding: 51.50m at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.